TFF, Union Therapeutics join on potential COVID-19 treatment
The companies will partner on developing dry-powder forms of niclosamide as a treatment for the virus, using thin-film freezing technology.
The companies will partner on developing dry-powder forms of niclosamide as a treatment for the virus, using thin-film freezing technology.
The companies will work together on solutions designed to enable sponsors to improve imaging, respiratory and cardiac safety data on decentralized trials.
The clinical trials marketplace company reportedly is connecting sites with 10,000 patients a month, with 40% of them from non-white groups.